| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Molecular and Cellular Biology, December 2006, p. 8880-8891, Vol. 26, No. 23
0270-7306/06/$08.00+0 doi:10.1128/MCB.00751-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
,
,1
Sanda Tamarut,1
Melanie Sticker-Jantscheff,2
Martina Barki
,1
Davor Solter,3
Miljana Uzelac,1
Kristina Grabu
i
,1 and
Sini
a Volarevi
1*
Department of Molecular Medicine and Biotechnology, School of Medicine, University of Rijeka, Rijeka, Croatia,1 Institute of Cell Biology, Swiss Federal Institute of Technology (ETH), Zurich, Switzerland,2 Department of Developmental Biology, Max Planck Institute of Immunobiology, Freiburg, Germany3
Received 1 May 2006/ Returned for modification 18 June 2006/ Accepted 15 September 2006
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
There is a large amount of nascent ribosome synthesis during the growth phase of the developing mouse oocyte (24). Since maternally inherited ribosomes are rapidly exhausted during the first three cleavages, nascent ribosome biogenesis is activated in the six- to eight-cell-stage embryo (22). After a relatively silent period of ribosome biogenesis in the blastocyst, this process is again dramatically up-regulated during gastrulation, which is associated with the start of a huge increase in the rate of proliferation and differentiation (33). It could be anticipated that an error in ribosome biogenesis would have pronounced effects on these three developmental periods through impaired protein translation (22, 24, 33).
We hypothesized that a defect in ribosome biogenesis could negatively affect oogenesis and embryonic development not only through impaired translation of specific mRNAs but also via activation of a checkpoint regulatory mechanism (10, 13, 37, 41, 44, 48, 56).
In order to gain insight into the processes which govern ribosomal biogenesis during oogenesis and embryogenesis, we conditionally inactivated one allele of the ribosomal protein S6 gene in growing oocytes and generated S6-heterozygous embryos. We show that S6 gene haploinsufficiency is associated with the activation of a p53-dependent checkpoint during gastrulation. Genetic inactivation of p53 bypassed this checkpoint and prolonged development of S6-heterozygous embryos until embryonic day 12.5 (E12.5), when they died with decreased expression of D-type cyclins, greatly diminished fetal liver erythropoiesis, and placental defects.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Histological analysis and immunohistochemistry. Embryos and ovaries were fixed overnight in 10% formalin and embedded in paraffin. Sections 4 µm thick were cut and stained with hematoxylin and eosin (H&E). For immunohistochemistry, anti-p53 (Novocastra Laboratories), anti-phospho-ATM/ATR substrate (Cell Signaling Technology), and anti-phospho-Ser139-histone H2A.X (Cell Signaling Technology) primary antibodies were used. Biotinylated anti-rabbit antibody was used as the secondary antibody, and detection was done by using an ABC system with diaminobenzidine substrate (Vector Lab).
Detection of BrdU-labeled and apoptotic cells. 5-Bromo-2'-deoxyuridine (5-BrdU) (100 µg/gram of body weight) was injected intraperitoneally into pregnant females (Sigma-Aldrich Chemie GmbH). The females were sacrificed 1 h after injection, and deciduas were processed for immunohistochemistry. 5-BrdU-positive cells were detected using a BrdU in situ detection kit (BD Biosciences Pharmingen). Apoptotic cells were identified by immunohistochemistry using antibody against activated caspase-3 (Cell Signaling Technology). BrdU-positive cells and apoptotic cells were counted on serial sections, and the number was compared to the total number of cells.
Detection of mitotic cells. Mitotic cells were counted on H&E-stained histological sections of embryos, and the number was compared to the total number of cells.
Blastocyst outgrowth. E3.5 embryos (blastocysts) were flushed from uterine horns with DMEM plus 10% serum and 25 mM HEPES (pH 7.4) and cultured individually on gelatinized plates at 37°C in 5% CO2 in ES-DMEM without leukemia inhibitory factor (31). After five days in culture, embryos were analyzed by phase-contrast microscopy (IX 71; Olympus) and scraped, and their genotype was determined by PCR.
RNA isolation and Northern blot analysis. Total RNA was extracted from E9.5 embryos using TRIzol (Invitrogen Life Technologies). RNA was separated on 1% agarose/formaldehyde gel and transferred to Hybond N+ membrane (Amersham Biosciences), hybridized at 52°C with cDNA probes labeled, and detected with an AlkPhosDirect Kit (Amersham Biosciences).
Analysis of rRNA processing. Mouse embryonic fibroblasts (MEFs) were starved for 30 min in methionine-free medium, incubated for 30 min with 25 µCi/ml L-[methyl-3H]methionine (Amersham Biosciences), and then chased in medium containing nonradioactive methionine for 5 min. Total RNA, isolated from the same number of cells, was separated on a formaldehyde-agarose gel and blotted to the Hybond N+ membrane, which was dried and treated with EN3HANCE (New England Nuclear) and exposed to Kodak BioMax MS film (Sigma).
rRNA processing in embryos was analyzed by Northern blotting using a specific 5' external transcribed sequence (5'ETS) rRNA probe. The 5'ETS probe was generated by PCR of genomic DNA by using the following primers: 5'-TCCAAGTGTTCATGCCACGTGCCTC-3' (forward) and 5'-ACAAGAAACAGCGCGTGCACACACC-3' (reverse). Northern blotting was performed as described above, except that the membrane was hybridized at 45°C.
CFSE labeling. Cell division of serum-stimulated MEFs was analyzed using 5 µM 5-6-carboxyfluorescein diacetate succinimidyl ester (CFSE) labeling (Molecular Probes). This method is based on the approximately twofold decreases in CFSE fluorescence after each cell division (29). Briefly, MEFs (106/ml of phosphate-buffered saline) were incubated with CFSE at 37°C for 10 min in CO2 incubator, washed twice with 2% fetal calf serum (FCS) in phosphate-buffered saline, plated, and stimulated with 10% FCS in DMEM for 96 h. CFSE intensity was analyzed by flow cytometry on FACScan (Becton Dickinson) using Cell Quest software. Ten thousand events were collected.
Immunoblotting. Embryo lysates were prepared with radioimmunoprecipitation assay buffer (44). Fifty micrograms of total proteins was electrophoresed on polyacrylamide gels. Western blots were probed with antibodies against the following proteins: actin, Cdk4 (Chemicon International), cyclin D1, cyclin D3, cyclin E, Cyclin A, Cdk2, P-RB-S780 (all from Santa Cruz Biotechnology), retinoblastoma protein (RB) (BD Pharmingen), P-RB-T821 (Abcam), ribosomal protein S6 (a kind gift from George Thomas and Stefano Fumagalli), and L11 (produced by immunization of rabbits with a synthetic peptide, corresponding to amino acid residues 150 to 169). Primary antibodies were detected by using horseradish peroxidase-conjugated antibodies (Santa Cruz Biotechnology) and an ECL kit (Amersham Biosciences).
In vitro hematopoietic colony assays. Fetal livers were collected from E12.5 embryos, and single-cell suspensions were prepared. An aliquot was counted to determine the nucleated cell number. In each 35-mm dish, 2 x 104 cells were plated in triplicate in methylcellulose medium containing 50 ng/ml stem cell factor, 10 ng/ml interleukin 3 (IL-3), 10 ng/ml IL-6, and 3 U/ml erythropoietin (MethoCult M3434; Stem Cell Technologies). BFU-E (burst-forming units-erythroid) colonies were counted after 9 days (23).
Flow cytometry. Single cell suspensions from fetal livers were washed in Iscove's modified Dulbecco's medium (Stem Cell Technologies) containing 2% FCS at 4°C, and 1 x 106 cells were stained with monoclonal antibodies to c-kit and Ter-119 (both from Pharmingen). Flow cytometry was performed with a FACScan (Becton Dickinson) using Cell Quest software. Ten thousand events were collected.
Quantitative RT-PCR. Total RNA was extracted and purified from embryos using TRIzol reagent (Invitrogen Life Technologies). One µg of total RNA was reverse transcribed to cDNA with random hexamers using a SuperScript III first-strand synthesis system for real-time PCR (RT-PCR) (Invitrogen Life Technologies). For the quantitative RT-PCRs, cDNA was diluted 1:120 and amplified using a LightCycler (Roche) and a LightCycler FastStart DNA Master SYBR Green I kit (Roche) with the following primers: for cyclin D1, 5'-CTGACACCAATCTCCTCAACG-3' (forward) and 5'-GCCAGGTTCCACTTGAGC-3' (reverse); for cyclin D3, 5'-AAAGGAGATCAAGCCGCACAT-3' (forward) and 5'-GTTCATAGCCAGAGGGAAGACATC-3' (reverse). For internal control we used the following primers for actin: 5'-TTCCTATGTGGGCGACGAGG-3' (forward) and 5'-CTCCTTAATGTCACGCACGATTTC-3' (reverse). The relative quantification of gene expression was calculated as described by the manufacturer.
| RESULTS |
|---|
|
|
|---|
|
To assess if S6wt/lox/Zp3-Cre+ oocytes differentiated into fertilization-competent egg cells and to determine the consequence of deletion of one S6 allele on embryonic development, the number of embryos and their morphology were analyzed at different days of gestation (31) (Fig. 1B). No significant morphological differences between mutant and wild-type E5.5 embryos were observed. Approximately half of the E6.5 embryos were smaller than the others, and all of these were S6wt/del mutants. Mutant E7.5 embryos were also smaller than their wild-type counterparts and did not appear to progress significantly beyond E6.5. The expected 1:1 ratio of S6wt/wt to S6wt/del embryos was observed until E7.5. At E8.5, wild-type embryos developed past the gastrulation stage with a distinct anterior-posterior pattern, whereas all E8.5 mutant embryos were in resorption (Fig. 1B; see Table S1 in the supplemental material).
S6-heterozygous embryos die during gastrulation. The time of apparent developmental failure of S6wt/del embryos coincides with gastrulation. During this developmental period, dramatic increases in the rate of cell proliferation are followed by the establishment of the three primary germ layers (33). To understand the developmental defect of S6wt/del embryos in greater detail, we compared H&E-stained histological sections of S6wt/wt and S6wt/del E5.5, E6.5, E7.5, and E8.5 embryos (31) (Fig. 1C). Both mutant and control E5.5 embryos displayed the characteristic elongated egg cylinder. Wild-type E6.5 embryos showed a clear morphological distinction between the embryonic and extraembryonic ectoderm and between the embryonic and extraembryonic endoderm (Fig. 1C). In contrast, E6.5 mutant embryos exhibited a reduced and disorganized embryonic and extraembryonic region. Additionally, a change in the shape of the cells was observed (Fig. 1C). Wild-type E7.5 embryos increased in size and further progressed in their development, while mutant embryos did not. By E8.5, all S6wt/del embryos were being resorbed (Fig. 1C).
Extraembryonic tissue allows embryos to attach to the uterus during implantation, conveys nutrients to the embryo, removes its waste products, and later participates in the formation of the placenta. To determine its contribution to the mutant phenotype in vivo, we crossed S6lox/lox females with Sox2-Cre males to specifically delete one S6 allele in the epiblast at early gastrulation stages (12). Growth of the embryonic but not extraembryonic region was inhibited in E7.5 S6wt/lox/Sox2-Cre+ embryos (Fig. 1D). As a consequence, S6wt/lox/Sox2-Cre+ embryos died by E8.5, indicating that the mutant phenotype could not be rescued with wild-type extraembryonic tissue (Fig. 1E). A PCR analysis of DNA isolated S6wt/lox/Sox2-Cre+ embryos showed that one S6 allele is deleted in the embryonic but not extraembryonic region (data not shown). To assess if S6wt/del embryos will manifest any pathology when grown in culture, where rates of cell division are slower (13), E3.5 blastocysts obtained from crosses between S6wt/lox/Zp3-Cre+ females and wild-type males were isolated and individually cultured in vitro (31) (Fig. 1F). Sixty-nine out of seventy-four blastocysts attached to the plate after three days in culture. After five days in culture, the inner cell mass, which contributes to formation of the embryo, was absent in 100% of S6wt/del embryo outgrowths (n = 29) and only 22.5% of control embryos (n = 40) (Fig. 1F). In contrast, S6wt/del mutation did not affect giant trophoblast cells that contribute to the development of the extraembryonic tissue (Fig. 1F). These results suggest that the phenotype of S6wt/del embryos is not merely a consequence of extremely fast cell division during gastrulation in vivo (33).
Proliferative defect and increased apoptosis of S6-heterozygous embryonic cells at gastrulation. To determine if developmental failure of S6wt/del embryos is caused by perturbation of the cell cycle, we measured the incorporation of 5-BrdU into DNA of E6.5 mutant and control embryos in vivo (13). The percentages of 5-BrdU-labeled cells were similar in mutant and control embryos (Fig. 2A and B), indicating that G1/S transition in S6wt/del E6.5 embryos is not impaired. Surprisingly, the percentage of mitotic figures was dramatically decreased in the embryonic region but only slightly decreased in the extraembryonic regions of S6wt/del embryos (Fig. 2C and D), suggesting that E6.5 S6wt/del embryonic cells failed to enter mitosis (21). The dephosphorylation of Tyr15-Cdk1 is associated with the G2/M transition. E6.5 S6wt/wt mitotic cells weakly stained for phosphorylated Tyr-15-Cdk1, while the remaining cells strongly stained. In contrast, all S6wt/del embryonic cells, except rare mitotic cells, stained for phosphorylated Tyr15-Cdk1 (Fig. 2E). In addition, there was no difference in staining with anti-Cdk1 antibodies between mutant and control embryos (data not shown). These results suggest that the deletion of one S6 allele prevents cells from entering the M phase by inhibiting dephosphorylation and activation of Cdk1, although we do not have any direct evidence for a causal relationship between these two events. Together, these results could largely explain the phenotype of S6wt/del embryos.
|
S6 heterozygosity triggers a p53-dependent checkpoint during gastrulation. There are at least two models that could explain the phenotype of S6wt/del embryos. One is that a reduced level of S6 is rate limiting for ribosome biogenesis and may constitute a bottleneck for protein synthesis in highly proliferative cells at gastrulation (33). The other possibility is that the embryonic cells possess molecular mechanisms that sense an error in ribosome biogenesis at the onset of gastrulation and eliminate potentially defective cells (10, 13). A number of different stresses activate the tumor suppressor p53 (47). We hypothesized that a defect in a component of the 40S ribosome could also trigger this stress response. We first compared the protein expression of p53 in S6wt/wt and S6wt/del embryos. No staining was observed in S6wt/wt E6.5 embryos, while the majority of S6wt/del cells strongly stained with anti-p53 antibodies (Fig. 3A).
|
Impaired translation of mRNAs encoding key DNA damage repair or replication proteins could lead to DNA damage and the induction of p53 in S6wt/del embryos (47). Histological sections of these embryos did not stain positive with antibodies against the ATM/ATR phosphorylated consensus sequence or histone H2A.X phosphorylated on Ser139, suggesting that the DNA damage is not responsible for the induction of p53 in S6-deficient embryonic cells (2) (Fig. 3F).
Next, we wanted to elucidate the molecular mechanisms that increase p53 levels in S6-deficient embryonic cells. The nucleolar protein p19Arf regulates p53 levels under stress conditions (reviewed in reference 28). We speculated that, upon perturbations in ribosome biogenesis in S6wt/del embryonic cells, p19Arf becomes accessible to bind and antagonize Mdm2 function and activate p53. Interestingly, genetic inactivation of p19Arf did not rescue the lethality of S6-heterozygous embryos at gastrulation, suggesting that p19Arf is not required for this checkpoint response (55) (Fig. 3G).
We set out to determine molecules that may function downstream of p53 in this checkpoint regulatory pathway. A candidate gene is the cell cycle inhibitor p21CIP1, a transcriptional target of the p53 tumor suppressor. Therefore, we genetically inactivated p21CIP1 in S6wt/del embryos (4). S6wt/del/p21CIP1/ embryos were significantly smaller and more developmentally retarded than S6wt/del/p53/ embryos at E8.5 and E9.5 (Fig. 3H), indicating that p21CIP1 only partially accounts for the effect of p53 in S6wt/del embryos during gastrulation, probably because p53 can still induce apoptosis as well as inhibit ribosome biogenesis.
Ribosome biogenesis defect in S6wt/del/p53/ embryos. To gain insight into the postgastrulation development of S6wt/del/p53/ embryos, we analyzed their number and morphology at different stages. These embryos were detected at the expected Mendelian distribution until E10.5, about half of them were still viable at E12.5, but no live mutant embryos were observed at E13.5 (see Table S2 in the supplemental material). S6wt/del/p53/ embryos were smaller than their S6wt/wt/p53/ littermates from gastrulation to E12.5 (Fig. 3B and E and data not shown).
To understand how the S6wt/del mutant genotype is responsible for the phenotype of S6wt/del/p53/ embryos, we first determined the level of S6 protein. S6 was significantly decreased, but there was no effect on L11 ribosomal protein (Fig. 4A). A Northern blot analysis of total RNA isolated from E10.5 S6wt/del/p53/ embryos employing 5'ETS, ITS-1 (internal transcribed sequence 1), and 18S rRNA specific probes revealed that they accumulated 34S rRNA precursor, suggesting an rRNA processing defect (Fig. 4B and data not shown). The same rRNA precursor also accumulated in E12.5 S6wt/del/p53/ embryos (Fig. 4B and data not shown) as well as in S6-deficient livers and T cells (44, 48). Most likely, as a consequence of this processing defect, the amounts of 18S and 28S rRNAs were significantly decreased in S6wt/del/p53/ embryos, suggesting a serious deficiency in the amount of 40S and 60S ribosomal subunits, respectively (Fig. 4C).
|
|
|
|
At the E12.5 stage, the total number of cells per liver was decreased from 4.32 ± 0.85 x 106 in S6wt/wt/p53/ (n = 12) to 0.48 ± 0.03 x 106 in S6wt/wt/p53/ (n = 10) embryos. The compiled results, expressed in terms of the absolute number of cells in each population, showed that there were 1.6- and 3.8-fold decreases in the total number of cells in the R1 and R4 populations, respectively. A 4.7-fold reduction in the number of cells in the R2 population was observed. Strikingly, the R3 population of erythroid differentiating cells was compromised to a much greater degree (31-fold) (Fig. 7D). To analyze this phenotype further, we next plated equal numbers of E12.5 S6wt/wt/p53/ and S6wt/del/p53/ fetal liver cells in methylcellulose in the presence of various cytokines and tested the ability of erythroid progenitors to form BFU-E (Fig. 7E). Interestingly, these experiments revealed that the numbers of BFU-E colonies were increased 3.8-fold in the S6wt/del/p53/ fetal liver cell population relative to the S6wt/wt/p53/ controls (Fig. 7E), most likely due to a higher representation of c-kit-positive and Ter-119-negative progenitor cells in the mutant fetal liver (R1 population in Fig. 7C). A severely diminished erythropoiesis in E12.5 S6wt/del/p53/ embryos is likely the result of a modest reduction in the number of erythroid progenitor cells in fetal livers (2.3-fold) (Fig. 7F) and a more severe block in erythropoietic differentiation in vivo (Fig. 7C and D). Interestingly, the size of the colonies formed from individual progenitor cells was indistinguishable between the genotypes (Fig. 7G), suggesting that the intrinsic potential of S6wt/del/p53/ erythroid progenitors to differentiate in vitro is not significantly altered. The mutant embryos were not obviously anemic, although this is most certainly because of sufficient yolk sac-derived primitive erythropoiesis, which is still active at E12.5 (Fig. 7A and data not shown). Since primitive erythropoiesis ceases after E12.5, there is the possibility that, in the absence of sufficient fetal liver erythropoiesis, S6wt/del/p53/ embryos die as a result of anemia. Interestingly, mutations in the ribosomal protein S19 gene are associated with some cases of Diamond-Blackfan anemia, which is characterized by absent or decreased erythropoiesis (9).
Morphological examination revealed that the size of S6wt/del/p53/ placentas was reduced (Fig. 7A). To study placental structure in detail, we performed a histological analysis. H&E staining of a histological section of S6wt/del/p53/ placenta showed that numbers of labyrinths and spongiotrophoblasts were significantly reduced relative to the S6wt/wt/p53/ control. Interestingly, the number of trophoblast giant cells was markedly reduced (Fig. 7H). These results suggest that placental defects could be responsible for the lethality of the mutant embryos. Further investigations will be required to determine the exact cause of death of S6wt/del/p53/ embryos and the contributions of the observed placental phenotype and/or deficient definitive erythropoiesis to the lethality (39).
| DISCUSSION |
|---|
|
|
|---|
, Cdc25C, etc.) and apoptosis (Puma, Bax, and Noxa) (47). Since p21CIP1 only partially accounts for the effect of p53 to the phenotype (Fig. 3H), it will be necessary to determine the contribution of other candidate genes to the cell cycle block and apoptosis in S6wt/del embryos. A normal embryonic development of mice whose S6 phosphorylation sites were mutated suggests that a decrease in phospho-S6 does not trigger a checkpoint response (42).
What are the consequences of S6 heterozygosity on the embryonic development in the absence of p53? Since the translation of specific mRNAs depends on their affinity for ribosome, a defect in ribosome biogenesis in S6wt/del embryos could change the accuracy of protein translation and alter the precise execution of the developmental program (26). Interestingly, despite a defect in ribosome biogenesis, E12.5 S6wt/del/p53/ MEFs show normal expression of cyclin D1 and D3 proteins, proliferation rates, and sizes. How can these results explain the size difference between S6wt/del/p53/ and S6wt/wt/p53/ embryos? We found that the incorporation of BrdU in most tissues of E11.5 S6wt/del/p53/ embryos was slightly decreased in comparison to their S6wt/wt/p53/ counterparts, except for liver, which incorporated significantly less BrdU. A slight decrease in BrdU incorporation in S6wt/del/p53/ relative to S6wt/wt/p53/ embryos could at least partially account for the size discrepancies between S6wt/del/p53/ and S6wt/wt/p53/ embryos. Furthermore, we cannot formally rule out the possibility that a larger defect in proliferation exists in S6wt/del/p53/ embryos during specific stages of the development. The fact that S6wt/del/p53/ embryos develop as late as E12.5, when most of the tissues and organs are already formed, indicates that a serious deficiency in the amount of ribosomes in these embryos does not significantly affect the translation of the majority of mRNAs. Indeed, there was no effect on cyclin A, cyclin E, Cdk2, Cdk4, L11, and actin protein levels in these embryos. In contrast, the protein levels of cyclins D1 and D3 were decreased. The observation that the expression of cyclin D1 and D3 mRNAs was normal in S6wt/del/p53/ embryos suggests a specific defect in their translation. The protein levels of D-type cyclins were more severely compromised within the S6wt/del/p53/ fetal liver than in the remaining parts of the embryo. These results suggest that decreased levels of D-type cyclins are responsible for the proliferation defect in the mutant fetal liver. However, direct evidence in support of this notion is lacking.
As the progenitors from S6wt/del/p53/ fetal livers are capable of differentiating along the erythroid lineage in culture, the possibility exists that impaired erythropoiesis in the mutant liver may be secondary to a defect in the other tissues. A feasible candidate tissue that is responsible for the fetal liver phenotype in the mutant embryo may be the placenta, as there are defects in this tissue and placenta has been suggested to influence definitive erythropoiesis in the fetal liver (16). Combining S6wt/del/p53/ with tetraploid wild-type embryos should help in determining the role of S6wt/del/p53/ placenta in the mutant fetal liver phenotype and/or the lethality of the embryos (31).
The fact that S6wt/del/p53/ embryos die at an earlier developmental stage than embryos lacking all D-type cyclins suggests a defective translation of some other mRNAs. It will be challenging to identify them and determine how their translational defects contribute to the phenotype of these embryos. One could also imagine that an uncharacterized p53-independent checkpoint contributes to the phenotype S6-heterozygous embryos. These are difficult issues that have to be addressed in the future.
The finding that a p53-dependent checkpoint prevents the development of S6-heterozygous embryos during gastrulation, despite the fact that their protein translation is sufficient to allow their development (although aberrant) until E12.5, suggests that the molecular mechanisms have evolved during mammalian evolution; these mechanisms strongly guard against potential heterozygosity for the ribosomal protein S6 gene and possibly other ribosomal protein genes. Since some ribosomal protein genes are suggested to be tumor suppressors (1, 9, 50), we speculate that the failure to activate a p53-dependent checkpoint when an error in ribosome biogenesis or defective ribosomes are present could potentially lead to the development of malignant tumors (32). Additionally, the activation of this checkpoint might play an important role in development, senescence, and aging.
| ACKNOWLEDGMENTS |
|---|
iki
, and Stefano Fumagalli for readings of the manuscript; Drago Batini
and Tihomila Bu
i
for technical advice; and Barbara Knowles and Charles Sherr for providing Zp3-Cre transgenic mice and p19Arf knockout mice, respectively. This work was supported by grants from SNSF and the Ministry of Science, Education, and Sports of Croatia.
| FOOTNOTES |
|---|
e Branchetta 20, 51000, Rijeka, Croatia. Phone: 385-51 651 120. Fax: 385-51 651 197. E-mail: vsinisa{at}medri.hr.
Published ahead of print on 25 September 2006. ![]()
Supplemental material for this article may be found at http://mcb.asm.org/. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Bartkova, J., Z. Horejsi, K. Koed, A. Kramer, F. Tort, K. Zieger, P. Guldberg, M. Sehested, J. M. Nesland, C. Lukas, T. Orntoft, J. Lukas, and J. Bartek. 2005. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434:864-870.[CrossRef][Medline]
3. Bhat, K. P., K. Itahana, A. Jin, and Y. Zhang. 2004. Essential role for ribosomal protein L11 in mediating growth inhibition-induced p53 activation. EMBO J. 23:2402-2412.[CrossRef][Medline]
4. Brugarolas, J., C. Chandrasekaran, J. I. Gordon, D. Beach, T. Jacks, and G. J. Hannon. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:552-557.[CrossRef][Medline]
5. Conlon, I., and M. Raff. 1999. Size control in animal development. Cell 96:235-244.[CrossRef][Medline]
6. Dai, M. S., and H. Lu. 2004. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J. Biol. Chem. 279:44475-44482.
7. Dai, M. S., S. X. Zeng, Y. Jin, X. X. Sun, L. David, and H. Lu. 2004. Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol. Cell. Biol. 24:7654-7668.
8. de Vries, W. N., L. T. Binns, K. S. Fancher, J. Dean, R. Moore, R. Kemler, and B. B. Knowles. 2000. Expression of Cre recombinase in mouse oocytes: a means to study maternal effect genes. Genesis 26:110-112.[CrossRef][Medline]
9. Draptchinskaia, N., P. Gustavsson, B. Andersson, M. Pettersson, T. N. Willig, I. Dianzani, S. Ball, G. Tchernia, J. Klar, H. Matsson, D. Tentler, N. Mohandas, B. Carlsson, and N. Dahl. 1999. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat. Genet. 21:169-175.[CrossRef][Medline]
10. Elledge, S. J. 1996. Cell cycle checkpoints: preventing an identity crisis. Science 274:1664-1672.
11. Hafen, E. 2004. Interplay between growth factor and nutrient signaling: lessons from Drosophila TOR. Curr. Top. Microbiol. Immunol. 279:153-167.[Medline]
12. Hayashi, S., P. Lewis, L. Pevny, and A. P. McMahon. 2002. Efficient gene modulation in mouse epiblast using a Sox2Cre transgenic mouse strain. Mech. Dev. 119(Suppl. 1):S97-S101.[CrossRef][Medline]
13. Heyer, B. S., A. MacAuley, O. Behrendtsen, and Z. Werb. 2000. Hypersensitivity to DNA damage leads to increased apoptosis during early mouse development. Genes Dev. 14:2072-2084.
14. Holland, E. J., N. Sonenberg, P. P. Pandolfi, and G. Thomas. 2004. Signaling control of mRNA translation in cancer pathogenesis. Oncogene 23:3138-3144.[CrossRef][Medline]
15. Honda, R., and H. Yasuda. 1999. Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J. 18:22-27.[CrossRef][Medline]
16. Ihle, J. N. 2000. The challenges of translating knockout phenotypes into gene function. Cell 102:131-134.[CrossRef][Medline]
17. Jacks, T., L. Remington, B. O. Williams, E. M. Schmitt, S. Halachmi, R. T. Bronson, and R. A. Weinberg. 1994. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4:1-7.[Medline]
18. Jin, A., K. Itahana, K. O'Keefe, and Y. Zhang. 2004. Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol. Cell. Biol. 24:7669-7680.
19. Jorgensen, P., J. L. Nishikawa, B. J. Breitkreutz, and M. Tyers. 2002. Systematic identification of pathways that couple cell growth and division in yeast. Science 297:395-400.
20. Jorgensen, P., and M. Tyers. 2004. How cells coordinate growth and division. Curr. Biol. 14:R1014-1027.[CrossRef][Medline]
21. Kastan, M. B., and J. Bartek. 2004. Cell-cycle checkpoints and cancer. Nature 432:316-323.[CrossRef][Medline]
22. Kopecny, V., V. Landa, and A. Pavlok. 1995. Localization of nucleic acids in the nucleoli of oocytes and early embryos of mouse and hamster: an autoradiographic study. Mol. Reprod. Dev. 41:449-458.[Medline]
23. Kozar, K., M. A. Ciemerych, V. I. Rebel, H. Shigematsu, A. Zagozdzon, E. Sicinska, Y. Geng, Q. Yu, S. Bhattacharya, R. T. Bronson, K. Akashi, and P. Sicinski. 2004. Mouse development and cell proliferation in the absence of D-cyclins. Cell 118:477-491.[CrossRef][Medline]
24. LaMarca, M. J., and P. M. Wassarman. 1979. Program of early development in the mammal: changes in absolute rates of synthesis of ribosomal proteins during oogenesis and early embryogenesis in the mouse. Dev. Biol. 71:103-119.
25. Lambertsson, A. 1998. The minute genes in Drosophila and their molecular functions. Adv. Genet. 38:69-134.[Medline]
26. Lodish, H. F. 1974. Model for the regulation of mRNA translation applied to haemoglobin synthesis. Nature 251:385-388.[CrossRef][Medline]
27. Lohrum, M. A., R. L. Ludwig, M. H. Kubbutat, M. Hanlon, and K. H. Vousden. 2003. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 3:577-587.[CrossRef][Medline]
28. Lowe, S. W., and C. J. Sherr. 2003. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Dev. 13:77-83.[CrossRef][Medline]
29. Lyons, A. B., and C. R. Parish. 1994. Determination of lymphocyte division by flow cytometry. J. Immunol. Methods 171:131-137.[CrossRef][Medline]
30. Marechal, V., B. Elenbaas, J. Piette, J. C. Nicolas, and A. J. Levine. 1994. The ribosomal protein L5 protein is associated with Mdm-2 and Mdm-2-p53 complexes. Mol. Cell. Biol. 14:7414-7420.
31. Nagy, A., M. Gertsenstein, K. Vintersten, and R. Behringer. 2003. Manipulating the mouse embryo: a laboratory manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
32. Nurse, P. 2000. A long twentieth century of the cell cycle and beyond. Cell 100:71-78.[CrossRef][Medline]
33. O'Farrell, P. H., J. Stumpff, and T. T. Su. 2004. Embryonic cleavage cycles: how is a mouse like a fly? Curr. Biol. 14:R35-45.[Medline]
34. Olson, M. O. J. 2004. Sensing cellular stress: another new function